{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T10:29:06Z","timestamp":1791368946885,"version":"4.3.1"},"reference-count":125,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Various therapeutic strategies have been developed to treat Pancreatic Cancer (PaCa). Unfortunately, most efforts have proved unfruitful, as the poor prognosis observed in this disease has only attained little improvement in the past 40 years. Recently, deeper understanding of the immune system and its interaction with malignant tumors have allowed significant advances in immunotherapy. Consistent with this, some of the most promising approaches are those that involve T-cell redirection to the tumor site, such as bispecific T-cell engagers (BiTEs). These recombinant antibodies bridge cytotoxic T-cells to tumor cells, inducing target cell-dependent polyclonal T-cell activation\/proliferation, which in turn results in elimination of bound tumor cells. Blinatumomab, an anti-CD19 BiTE, received FDA approval in 2014 for Precursor B-cell Acute Lymphoblastic Leukemia. In the past decade, it has demonstrated impressive clinical benefit in patients with B-cell leukemias; and other T-cell engagers have been FDA-approved for hematological malignancies and other diseases, yet limited effect has been observed with other BiTEs against solid cancers, including PaCa. Nevertheless, on May 2024, Tarlatamab, an anti-DLL3 BiTE was approved by the FDA for extensive small cell lung cancer, becoming the first BiTE for solid tumors. In this review, the generation of BiTEs, therapeutic features, manufacturing issues as well as the remaining challenges and novel strategies of BiTE therapy in the context of PaCa, including the lessons we can learn from the use of BiTEs on other types of cancer will be explored.<\/jats:p>","DOI":"10.3389\/fonc.2024.1429330","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T05:20:12Z","timestamp":1734672012000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["10 years of BiTE immunotherapy: an overview with a focus on pancreatic cancer"],"prefix":"10.3389","volume":"14","author":[{"given":"Solange R.","family":"Paredes-Moscosso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit C.","family":"Nathwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"B3","article-title":"The treatment of Malignant tumors by repeated inoculations of erysipelas: With a report of ten original cases","author":"Coley","year":"1893","journal-title":"Clin Orthop Relat Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/cber.19090420105","article-title":"\u00dcber Den Jetzigen Stand Der Karzinomforschung Beitr\u00e4ge zur experimentellen","author":"Ehrlich","year":"1909","journal-title":"Pathologie und Chemotherapie"},{"key":"B5","volume-title":"Cellular and Humoral Aspects of the Hypersensitive States: A Symposium Held at the New York Academy of Medicine","author":"Lawrence","year":"1959"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(67)92837-1","article-title":"Immunological aspects of Malignant disease","volume":"289","author":"Burnet","year":"1967","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/35074122","article-title":"IFNgamma and lympohcytes prevent primary tomour development and shape tomour immunogenicity","volume":"410","author":"Shankaran","year":"2001","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.22.012703.104803","article-title":"The three Es of cancer immunoediting","volume":"22","author":"Dunn","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"O\u2019Donnell","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(05)80055-8","article-title":"Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7\/BB1 in interleukin-2 production and immunotherapy","volume":"71","author":"Schwartz","year":"1992","journal-title":"Cell"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00418","article-title":"Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators","volume":"6","author":"Le Mercier","year":"2015","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1187802","article-title":"Bispecific antibodies in cancer immunotherapy","volume":"12","author":"Chen","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1177\/2515135518763280","article-title":"Bispecific antibodies in cancer immunotherapy","volume":"6","author":"Dahl\u00e9n","year":"2018","journal-title":"Ther Adv Vaccines Immunotherapy"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.25","article-title":"The future of cancer treatment: Immunomodulation, CARs and combination immunotherapy","volume":"13","author":"Khalil","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: The cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"B18","article-title":"Advances in cancer immunology and cancer immunotherapy","volume":"21","author":"Voena","year":"2016","journal-title":"Discovery Med"},{"key":"B19","volume-title":"ROR1 as a target for cancer immunotherapy","author":"Paredes-Moscosso","year":"2017"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.2017.176.issue-1","article-title":"The expanding role of the clinical haematologist in the new world of advanced therapy medicinal products","volume":"176","author":"Lowdell","year":"2017","journal-title":"Br J Haematology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1126\/science.342.6165.1432","article-title":"Breakthrough of the year 2013. Cancer immunotherapy","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Science"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"K\u00f6hler","year":"1975","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlich\u2019s magic bullet concept: 100 Years of progress","volume":"8","author":"Strebhardt","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-5890(03)00099-3","article-title":"The human antibody repertoire to infectious agents: Implications for disease pathogenesis","volume":"40","author":"Ohlin","year":"2003","journal-title":"Mol Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/mp.53.3.111","article-title":"Demystified\u2026: monoclonal antibodies","volume":"53","author":"Nelson","year":"2000","journal-title":"Mol Pathology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3236","article-title":"Antibody therapy of cancer","volume":"12","author":"Scott","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-10-42","article-title":"Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia","volume":"10","author":"Loisel","year":"2011","journal-title":"Mol Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2015.10.009","article-title":"Cancer immunotherapy: Strategies for personalization and combinatorial approaches","volume":"9","author":"Sathyanarayanan","year":"2015","journal-title":"Mol Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1773201","article-title":"Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients","volume":"9","author":"Lum","year":"2020","journal-title":"Oncoimmunology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2015.11.003","article-title":"Tumor microenvironment (TME)-driven immune suppression in B cell Malignancy","volume":"1863","author":"Nicholas","year":"2016","journal-title":"Biochim Biophys Acta - Mol Cell Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.2013.76.issue-2","article-title":"Novel antibodies targeting immune regulatory checkpoints for cancer therapy","volume":"76","author":"Lee","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2014.11.017","article-title":"The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: The Bristol-Myers Squibb experience","volume":"148","author":"Berman","year":"2015","journal-title":"Pharmacol Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nri2747","article-title":"Strategies and challenges for the next generation of therapeutic antibodies","volume":"10","author":"Beck","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B34","unstructured":"Bispecific Antibodies: An Area of Research and Clinical Applications\n          \n          \n          2024"},{"key":"B35","unstructured":"Bispecific antibodies come to the fore\n          \n          \n            \n              Reichert\n              J\n            \n          \n          \n          2020"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2017.12.002","article-title":"Bispecific antibodies for cancer therapy: A review","volume":"185","author":"Krishnamurthy","year":"2018","journal-title":"Pharmacol Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S151282","article-title":"Bispecific antibodies: Design, therapy, perspectives","volume":"12","author":"Sedykh","year":"2018","journal-title":"Drug Design Dev Ther"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1008339","article-title":"Are BiTEs the \u201cmissing link\u201d in cancer therapy","volume":"4","author":"Suryadevara","year":"2015","journal-title":"OncoImmunology"},{"key":"B39","article-title":"BiTE: Teaching antibodies to engage T-cells for cancer therapy","volume":"11","author":"Baeuerle","year":"2009","journal-title":"Curr Opin Mol Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2015.1041373","article-title":"Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer","volume":"15","author":"Stieglmaier","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1006\/jmbi.1999.3156","article-title":"Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics","volume":"293","author":"Kipriyanov","year":"1999","journal-title":"J Mol Biol"},{"key":"B42","article-title":"Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies","volume":"53","author":"Bohlen","year":"1993","journal-title":"Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2014.93","article-title":"Bispecific T-cell engagers for cancer immunotherapy","volume":"93","author":"Huehls","year":"2015","journal-title":"Immunol Cell Biol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.v100:6","article-title":"Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody","volume":"100","author":"Dreier","year":"2002","journal-title":"Int J Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01328","article-title":"Galectin-3 released by pancreatic ductal adenocarcinoma suppresses \u03b3\u03b4 T cell proliferation but not their cytotoxicity","volume":"11","author":"Gonnermann","year":"2020","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318156750c","article-title":"Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class","volume":"30","author":"Brischwein","year":"2007","journal-title":"J Immunotherapy"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181a1c097","article-title":"Antitumor activity of an EpCAM\/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of t-cell anergy and sustained cytokine release","volume":"32","author":"Amann","year":"2009","journal-title":"J Immunotherapy"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2011.03.010","article-title":"Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab","volume":"317","author":"Nagorsen","year":"2011","journal-title":"Exp Cell Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.v115:1","article-title":"Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-\/CD3-bispecific single-chain antibody construct","volume":"115","author":"Hoffmann","year":"2005","journal-title":"Int J Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1177\/1078155215618770","article-title":"A review of blinatumomab, a novel immunotherapy","volume":"22","author":"Newman","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26757","article-title":"Regulatory T cells are redirected to kill glioblastoma by an EGFRviii-targeted bispecific antibody","volume":"2","author":"Choi","year":"2013","journal-title":"Oncoimmunology"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2005.07.034","article-title":"MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors","volume":"43","author":"Brischwein","year":"2006","journal-title":"Mol Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2008.11.014","article-title":"Mode of cytotoxic action of T cell-engaging BiTE antibody MT110","volume":"214","author":"Haas","year":"2009","journal-title":"Immunobiology"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.4.1.18821","article-title":"World bispecific antibody summit, september 27-28, 2011, Boston, MA","author":"Dhimolea","year":"2012","journal-title":"MAbs"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.2147\/CPAA.S42689","article-title":"Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia","volume":"5","author":"Portell","year":"2013","journal-title":"Clin Pharmacology: Adv Appl"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-441030","article-title":"Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL","volume":"120","author":"Topp","year":"2012","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-015-0213-6","article-title":"Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19\/CD3-bispecific T cell engager antibody blinatumomab","volume":"8","author":"K\u00f6hnke","year":"2015","journal-title":"J Hematol Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.41","article-title":"Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL","volume":"31","author":"Duell","year":"2017","journal-title":"Leukemia"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-400515","article-title":"Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab","volume":"119","author":"Klinger","year":"2012","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell - Engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/0003-9861(61)90296-X","article-title":"Recombination of a mixture of univalent antibody fragments of different specificity","volume":"93","author":"Nisonoff","year":"1961","journal-title":"Arch Biochem Biophysics"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-017-0072-7","article-title":"The development of bispecific antibodies and their applications in tumor immune escape","volume":"6","author":"Zhang","year":"2017","journal-title":"Exp Hematol Oncol"},{"key":"B63","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V95.6.2098","article-title":"A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes","volume":"95","author":"L\u00f6ffler","year":"2000","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"MAbs"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v28.i32.4698","article-title":"International patterns in incidence and mortality trends of pancreatic cancer in the last three decades: A joinpoint regression analysis","volume":"28","author":"Ilic","year":"2022","journal-title":"World J Gastroenterol"},{"key":"B67","unstructured":"How is Immunotherapy for Pancreatic Cancer Changing the Outlook for Patients"},{"key":"B68","unstructured":"Cancer Tomorrow - Globocan 2022\n          \n          \n          \n          2024"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2012.10.002","article-title":"Pancreatic cancer: A comprehensive review and update","volume":"59","author":"Muniraj","year":"2013","journal-title":"Disease-a-Month"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.11628","article-title":"Pancreatic cancer stem cells and therapeutic approaches","volume":"37","author":"Ercan","year":"2017","journal-title":"Anticancer Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2018.03.040","article-title":"Immunotherapy for pancreatic cancer: A long and hopeful journey","volume":"425","author":"Xu","year":"2018","journal-title":"Cancer Lett"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2012.119","article-title":"New biomarkers and targets in pancreatic cancer and their application to treatment","volume":"9","author":"Costello","year":"2012","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.08.019","article-title":"Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials","volume":"49","author":"Ciliberto","year":"2013","journal-title":"Eur J Cancer"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.183","article-title":"A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study","volume":"106","author":"Nakai","year":"2012","journal-title":"Br J Cancer"},{"key":"B75","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/1746-1596-8-146","article-title":"Expression of CD44v6 and integrin-\u03b21 for the prognosis evaluation of pancreatic cancer patients after cryosurgery","volume":"8","author":"Zhou","year":"2013","journal-title":"Diagn Pathol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199202133260706","article-title":"Pancreatic carcinoma","volume":"326","author":"Warshaw","year":"1992","journal-title":"New Engl J Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21190","article-title":"Recent progress in pancreatic cancer","volume":"63","author":"Wolfgang","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-021-00556-2","article-title":"Pancreatic cancer: recent progress of drugs in clinical trials","volume":"23","author":"Zhang","year":"2021","journal-title":"AAPS J"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-015-1920-4","article-title":"Cancer stem cells: A potential target for cancer therapy","volume":"72","author":"Qiu","year":"2015","journal-title":"Cell Mol Life Sci"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0612","article-title":"FDA approval: blinatumomab","volume":"21","author":"Przepiorka","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603494","article-title":"EpCAM (CD326) finding its role in cancer","author":"Baeuerle","year":"2007","journal-title":"Br J Cancer"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-0654","article-title":"The emerging role of EpCAM in cancer and stem cell signaling","volume":"69","author":"Munz","year":"2009","journal-title":"Cancer Res"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1270","article-title":"EpCAM\/CD3-bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells","volume":"18","author":"Cioffi","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1450710","article-title":"A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM\/CD3 T-cell engager (BiTE\u00ae) antibody construct, in patients with refractory solid tumors","volume":"7","author":"Kebenko","year":"2018","journal-title":"Oncoimmunology"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2016.07.009","article-title":"Phase 1 dose escalation study of MEDI-565, a bispecific T-cell engager that targets human carcinoembryonic antigen, in patients with advanced gastrointestinal adenocarcinomas","volume":"15","author":"Pishvaian","year":"2016","journal-title":"Clin Colorectal Cancer"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.3514","article-title":"Phase I trial of hypoxia-responsive CEA CAR-T cell therapy in patients with heavily pretreated solid tumor via intraperitoneal or intravenous transfusion","volume":"42","author":"Zhang","year":"2024","journal-title":"J Clin Oncol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1326437","article-title":"An ROR1 bi-specific T-cell engager provides effective targeting and cytotoxicity against a range of solid tumors","volume":"6","author":"Gohil","year":"2017","journal-title":"Oncoimmunology"},{"key":"B88","unstructured":"Clinical-stage ROR1xCD3 bispecific antibodies with potential for broad cancer specificity\n          \n          \n            \n              Radziejewski\n              C\n            \n          \n          \n          2022"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-188607","article-title":"Time limited exposure to a ROR1 targeting bispecific T cell engager (NVG-111) leads to durable responses in subjects with relapsed refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL)","volume":"142","author":"Townsend","year":"2023","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0327-z","article-title":"The clinical role of the TME in solid cancer","volume":"120","author":"Giraldo","year":"2019","journal-title":"Br J Cancer"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2014.234","article-title":"Pancreatic disease in 2014: Pancreatic fibrosis and standard diagnostics","volume":"12","author":"Ceyhan","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198612253152606","article-title":"Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing","volume":"315","author":"Dvorak","year":"1986","journal-title":"N Engl J Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.66","article-title":"Pancreatic cancer biology and genetics from an evolutionary perspective","volume":"16","author":"Makohon-Moore","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.08.007","article-title":"Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy","volume":"159","author":"Sherman","year":"2014","journal-title":"Cell"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188425","article-title":"Progress and challenge in development of biotherapeutics targeting MET receptor for treatment of advanced cancer","volume":"1874","author":"Yao","year":"2020","journal-title":"Biochim Biophys Acta - Rev Cancer"},{"key":"B96","unstructured":"A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) (BoB)"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgu115","article-title":"Stromal reengineering to treat pancreas cancer","volume":"35","author":"Stromnes","year":"2014","journal-title":"Carcinogenesis"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.01.007","article-title":"Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma","volume":"21","author":"Provenzano","year":"2012","journal-title":"Cancer Cell"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1126\/science.1171362","article-title":"Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer","volume":"324","author":"Olive","year":"2009","journal-title":"Sci (1979)"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0175","article-title":"Dynamics of the immune reaction to pancreatic cancer from inception to invasion","volume":"67","author":"Clark","year":"2007","journal-title":"Cancer Res"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.07.025","article-title":"Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma","volume":"145","author":"Ene-Obong","year":"2013","journal-title":"Gastroenterology"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15095","article-title":"Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer","volume":"8","author":"Carstens","year":"2017","journal-title":"Nat Commun"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.4161\/21624011.2014.950171","article-title":"The pancreatic cancer microenvironment: An immunologic battleground","volume":"3","author":"Pillarisetty","year":"2014","journal-title":"Oncoimmunology"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01878","article-title":"Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: Current limitations and future options","volume":"9","author":"Kabacaoglu","year":"2018","journal-title":"Front Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2018.04.001","article-title":"Immunotherapy and prevention of pancreatic cancer","volume":"4","author":"Morrison","year":"2018","journal-title":"Trends Cancer"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10010006","article-title":"Immune evasion in pancreatic cancer: From mechanisms to therapy","volume":"10","author":"Martinez-Bosch","year":"2018","journal-title":"Cancers"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001191","article-title":"Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy","volume":"8","author":"Groeneveldt","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1343378","article-title":"Revolutionizing cancer treatment: the power of bi- and tri-specific T-cell engagers in oncolytic virotherapy","volume":"15","author":"Zarezadeh Mehrabadi","year":"2024","journal-title":"Front Immunol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S164542","article-title":"Site-specific PEGylation of an anti-CEA\/CD3 bispecific antibody improves its antitumor efficacy","volume":"13","author":"Pan","year":"2018","journal-title":"Int J Nanomedicine"},{"key":"B111","unstructured":"Pipeline\n          \n          \n          \n          2024"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-189058","article-title":"NVG-222: A first-in-class autoregulating half-life extended ROR1xCD3 T cell engager heralding a new class of safer drugs","volume":"142","author":"Granger","year":"2023","journal-title":"Blood"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0297","article-title":"CARs versus biTEs: A comparison between T cell\u2013redirection strategies for cancer treatment","volume":"8","author":"Slaney","year":"2018","journal-title":"Cancer Discovery"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1111\/imr.2016.270.issue-1","article-title":"Harnessing T cells to fight cancer with BiTE\u00ae antibody constructs - past developments and future directions","volume":"270","author":"Klinger","year":"2016","journal-title":"Immunol Rev"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete hematologic and molecular response in adult patients with relapsed\/refractory philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: Results from a phase II, single-arm, multicenter study","volume":"35","author":"Martinelli","year":"2017","journal-title":"J Clin Oncol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/Phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"Von Stackelberg","year":"2016","journal-title":"J Clin Oncol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e3182929056","article-title":"Expression of epithelial cell adhesion molecule in paired tumor samples of patients with primary and recurrent serous ovarian cancer","volume":"23","author":"Pietzner","year":"2013","journal-title":"Int J Gynecological Cancer"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-015-0241-7","article-title":"Solitomab, an EpCAM\/CD3 bispecific antibody construct (BiTE\u00ae), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro","volume":"34","author":"Ferrari","year":"2015","journal-title":"J Exp Clin Cancer Res"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy279.414","article-title":"Phase I study of AMG 211\/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed\/refractory gastrointestinal (GI) adenocarcinoma","volume":"29","author":"Moek","year":"2018","journal-title":"Ann Oncol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0256","article-title":"Pasotuxizumab, a BiTE\u00aeimmune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings","volume":"13","author":"Hummel","year":"2021","journal-title":"Immunotherapy"},{"key":"B121","unstructured":"Amgen receives FDA priority review for tarlatamab BLA\n          \n          \n          2023"},{"key":"B122","unstructured":"FDA Grants Priority Review to Amgen\u2019s Tarlatamab Application for Advanced Small Cell Lung Cancer\n          \n          \n          2023"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1111\/cas.v112.8","article-title":"Delta-like canonical Notch ligand 3 as a potential therapeutic target in Malignancies: A brief overview","volume":"112","author":"Matsuo","year":"2021","journal-title":"Cancer Sci"},{"key":"B124","unstructured":"FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer\n          \n          \n          \n          2024"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/8282391","article-title":"Clinical outcomes of specific immunotherapy in advanced pancreatic cancer: A systematic review and meta-analysis","volume":"2017","author":"Chen","year":"2017","journal-title":"J Immunol Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1429330\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T05:20:20Z","timestamp":1734672020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1429330\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":125,"alternative-id":["10.3389\/fonc.2024.1429330"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1429330","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,20]]},"article-number":"1429330"}}